Epilepsy, Complex Partial Clinical Trial
Official title:
Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects
This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring every 2-3 days until a maximum dose of 5mg per day is reached.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00143143 -
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
|
Phase 3 | |
Completed |
NCT01002820 -
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
|
Phase 2 | |
Completed |
NCT00001489 -
Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism
|
N/A | |
Completed |
NCT00425282 -
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
|
Phase 3 | |
Completed |
NCT00433667 -
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
|
Phase 3 | |
Completed |
NCT04573569 -
Neural Correlates of Cognition and Mood
|
||
Completed |
NCT00740623 -
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
|
Phase 3 | |
Completed |
NCT00744731 -
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
|
Phase 3 | |
Completed |
NCT00319501 -
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.
|
Phase 3 | |
Completed |
NCT00991757 -
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
|
Phase 3 | |
Completed |
NCT00056576 -
Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy
|
Phase 3 | |
Terminated |
NCT01128712 -
Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin
|
Phase 4 |